Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
ORTINLAB.NS Stock Summary
Top 10 Correlated ETFs
ORTINLAB.NS
In the News
ORTINLAB.NS Financial details
Company Rating
-
Market Cap
142.71M
Income
-3.43M
Revenue
68.58M
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
29
Optionable
No
Shortable
Yes
Earnings
14 Feb 2023
P/E
-41.6
Forward P/E
-
PEG
4.05
P/S
2.08
P/B
1.35
P/C
-
P/FCF
-
Quick Ratio
0.05
Current Ratio
0.8
Debt / Equity
-
LT Debt / Equity
0.23
-
-
EPS (TTM)
-0.03
EPS next Y
-
EPS next Q
-
EPS this Y
-142.24%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
NAN%
Revenue last 5Y
-36.5%
Revenue Q/Q
47.08%
EPS Q/Q
5500%
-
-
-
-
SMA20
-14.84%
SMA50
-18.55%
SMA100
-20.23%
Inst Own
-
Inst Trans
-
ROA
-2%
ROE
-3%
ROC
-
Gross Margin
44%
Oper. Margin
1%
Profit Margin
-5%
Payout
-
Shs Outstand
8.13M
Shs Float
4.85M
-
-
-
-
Target Price
-
52W Range
16.2-31.7
52W High
-44.52%
52W Low
+7.5%
RSI
24.03
Rel Volume
0.07
Avg Volume
71.5K
Volume
4.78K
Perf Week
-12.02%
Perf Month
-24.23%
Perf Quarter
-26.81%
Perf Half Y
-26.65%
-
-
-
-
Beta
1.15243
-
-
Volatility
1.49%, 1.66%
Prev Close
1.47%
Price
17.2
Change
-1.71%
ORTINLAB.NS Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-03-31
Metric | History | 2018-03-31 | 2019-03-31 | 2020-03-31 | 2021-03-31 | 2022-03-31 |
---|---|---|---|---|---|---|
Revenue per share | 98.02 | 200.79 | 241.24 | 10.02 | 10.12 | |
Net income per share | 0.84 | 1.57 | -0.69 | 1.16 | -0.49 | |
Operating cash flow per share | 1.92 | 4.07 | 7.66 | 22.13 | 2.65 | |
Free cash flow per share | 0.39 | 0.21 | 3.82 | 22.13 | 2.49 | |
Cash per share | 1.33 | 1.1 | 1.18 | 0.22 | 0.73 | |
Book value per share | 29.61 | 30.86 | 29.29 | 13.93 | 13.47 | |
Tangible book value per share | 29.61 | 30.86 | 29.29 | 13.93 | 13.47 | |
Share holders equity per share | 29.61 | 30.86 | 29.29 | 13.93 | 13.47 | |
Interest debt per share | 29.31 | 34.7 | 36.89 | 9.59 | 8.55 | |
Market cap | 313.39M | 242.24M | 118.58M | 252.68M | 183.89M | |
Enterprise value | 516.06M | 488.02M | 384.28M | 321.84M | 240.42M | |
P/E ratio | 46.14 | 18.93 | -21.03 | 26.72 | -46.12 | |
Price to sales ratio | 0.39 | 0.15 | 0.06 | 3.09 | 2.23 | |
POCF ratio | 20.11 | 7.32 | 1.9 | 1.4 | 8.54 | |
PFCF ratio | 98.95 | 140.19 | 3.82 | 1.4 | 9.07 | |
P/B Ratio | 1.3 | 0.97 | 0.5 | 2.23 | 1.68 | |
PTB ratio | 1.3 | 0.97 | 0.5 | 2.23 | 1.68 | |
EV to sales | 0.65 | 0.3 | 0.2 | 3.94 | 2.92 | |
Enterprise value over EBITDA | 10 | 8.6 | 7.48 | 24.85 | 41.85 | |
EV to operating cash flow | 33.12 | 14.74 | 6.17 | 1.78 | 11.17 | |
EV to free cash flow | 162.95 | 282.42 | 12.37 | 1.78 | 11.86 | |
Earnings yield | 0.02 | 0.05 | -0.05 | 0.04 | -0.02 | |
Free cash flow yield | 0.01 | 0.01 | 0.26 | 0.71 | 0.11 | |
Debt to equity | 2.06 | 3.19 | 3.89 | 0.87 | 0.89 | |
Debt to assets | 0.67 | 0.76 | 0.8 | 0.47 | 0.47 | |
Net debt to EBITDA | 3.93 | 4.33 | 5.17 | 5.34 | 9.84 | |
Current ratio | 1.26 | 1.14 | 1.1 | 0.78 | 0.76 | |
Interest coverage | 1.35 | 1.79 | 1.52 | 1.1 | 0.35 | |
Income quality | 2.29 | 2.59 | -11.04 | 19.07 | -5.4 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0.01 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | -0.8 | -0.95 | -0.5 | 0 | -0.06 | |
Capex to revenue | -0.02 | -0.02 | -0.02 | 0 | -0.02 | |
Capex to depreciation | -0.74 | -1.79 | -1.6 | 0 | -0.43 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 23.59 | 33.06 | 21.38 | 19.07 | 12.18 | |
ROIC | 0.07 | 0.09 | -0.05 | 0.33 | 0.01 | |
Return on tangible assets | 0.01 | 0.01 | 0 | 0.04 | -0.02 | |
Graham Net | -44.88 | -74.56 | -82.14 | -10.82 | -10.18 | |
Working capital | 107.33M | 98.65M | 85.85M | -17.61M | -18.61M | |
Tangible asset value | 240.78M | 250.94M | 238.16M | 113.56M | 109.57M | |
Net current asset value | 27.7M | 20.48M | -2.9M | -37.85M | -39.98M | |
Invested capital | 0.87 | 1.01 | 1.16 | 0.61 | 0.56 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 99.49M | 320.89M | 537.99M | 306.7M | 10.63M | |
Average inventory | 208.35M | 304.88M | 434.29M | 258.66M | 17.86M | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 105.09 | 126.25 | 136.69 | 123.67 | 61.78 | |
Days of inventory on hand | 152.23 | 98.03 | 113.68 | 169.25 | 136.6 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 3.47 | 2.89 | 2.67 | 2.95 | 5.91 | |
Inventory turnover | 2.4 | 3.72 | 3.21 | 2.16 | 2.67 | |
ROE | 0.03 | 0.05 | -0.02 | 0.08 | -0.04 | |
Capex per share | -1.53 | -3.86 | -3.84 | 0 | -0.15 |
Quarterly Fundamentals Overview
Last date of statement is 2022-12-31 for Q3
Metric | History | 2021-12-31 | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 |
---|---|---|---|---|---|---|
Revenue per share | 2.02 | 2.79 | 3.22 | 0.97 | 1.42 | |
Net income per share | -0.11 | -0.55 | -0.52 | 0.1 | 0.56 | |
Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
Cash per share | 0 | 0.72 | 0 | 0.39 | 0 | |
Book value per share | 0 | 13.35 | 0 | 13.05 | 0 | |
Tangible book value per share | 0 | 13.35 | 0 | 13.05 | 0 | |
Share holders equity per share | 0 | 13.35 | 0 | 13.05 | 0 | |
Interest debt per share | 0 | 7.78 | 0 | 8.62 | 0 | |
Market cap | 273.36M | 185.53M | 174.01M | 190.27M | 193.31M | |
Enterprise value | 0 | 242.05M | 0 | 257.41M | 0 | |
P/E ratio | -75.68 | -10.23 | -10.2 | 58.87 | 10.6 | |
Price to sales ratio | 16.48 | 8.09 | 6.64 | 24.19 | 16.71 | |
POCF ratio | 0 | 0 | 0 | 0 | 0 | |
PFCF ratio | 0 | 0 | 0 | 0 | 0 | |
P/B Ratio | 0 | 1.69 | 0 | 1.79 | 0 | |
PTB ratio | 0 | 1.69 | 0 | 1.79 | 0 | |
EV to sales | 0 | 10.55 | 0 | 32.73 | 0 | |
Enterprise value over EBITDA | 0 | -182.54 | 0 | -113.5 | 0 | |
EV to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
EV to free cash flow | 0 | 0 | 0 | 0 | 0 | |
Earnings yield | 0 | -0.02 | -0.02 | 0 | 0.02 | |
Free cash flow yield | 0 | 0 | 0 | 0 | 0 | |
Debt to equity | 0 | 0.89 | 0 | 0.9 | 0 | |
Debt to assets | 0 | 0.47 | 0 | 0.47 | 0 | |
Net debt to EBITDA | 0 | -42.63 | 0 | -29.6 | 0 | |
Current ratio | 0 | 0.76 | 0 | 0.8 | 0 | |
Interest coverage | 0.43 | -1.33 | 1.34 | -3.51 | 5.42 | |
Income quality | 0 | 0 | 0 | 0 | 0 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | 0 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 12.88 | 0 | 5.4 | 0 | |
ROIC | 0 | -0.01 | 0 | 0 | 0 | |
Return on tangible assets | 0 | -0.02 | 0 | 0 | 0 | |
Graham Net | 0 | -10.09 | 0 | -10.14 | 0 | |
Working capital | 0 | -18.61M | 0 | -13.19M | 0 | |
Tangible asset value | 0 | 109.57M | 0 | 106.12M | 0 | |
Net current asset value | 0 | -39.98M | 0 | -41.73M | 0 | |
Invested capital | 0 | 0.56 | 0 | 0.65 | 0 | |
Average receivables | 0 | 0 | 0 | 0 | 0 | |
Average payables | 0 | 0 | 0 | 0 | 0 | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
Days payables outstanding | 0 | 52.5 | 0 | 128.27 | 0 | |
Days of inventory on hand | 0 | 116.08 | 0 | 328.72 | 0 | |
Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
Payables turnover | 0 | 1.71 | 0 | 0.7 | 0 | |
Inventory turnover | 0 | 0.78 | 0 | 0.27 | 0 | |
ROE | 0 | -0.04 | 0 | 0.01 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
ORTINLAB.NS Frequently Asked Questions
What is Ortin Laboratories Limited stock symbol ?
Ortin Laboratories Limited is a IN stock and trading under the symbol ORTINLAB.NS
What is Ortin Laboratories Limited stock quote today ?
Ortin Laboratories Limited stock price is $17.2 today.
Is Ortin Laboratories Limited stock public?
Yes, Ortin Laboratories Limited is a publicly traded company.